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Background: Coronavirus has become a global concern in 2019-20. The virus 
belongs to the coronavirus family, which has been able to infect many patients 
and victims around the world. The virus originated in the Chinese city of 
Wuhan, which eventually spread around the world and became a pandemic.  
Materials and Methods: A total of 60 Patients with severe (n=30) and mild 
(n=30) symptoms of COIVD-19 were included in this study. Peripheral blood 
samples were collected from the patients. Real-time PCR was used to compare 
the relative expression levels of Procalcitonin and dipeptidyl peptidase IV 
(DPPIV) in a patient with severe and mild Covid-19 infection.  
Results: Procalcitonin and dipeptidyl peptidase IV markers in the peripheral 
blood of patients with severe symptoms, were positive in 29 (96.60%) and 26 
(86.60%), respectively (n=30); however, positive rates in the mild symptoms 
patients group were 27 (90%) and 25 (83.30%), respectively. There was a 
statistically significant difference between these two groups in terms of 
DDPIV and Procalcitonin (p<0.001).  
Conclusion: Procalcitonin and DPPIV increase in patients with COVID-19 
infection, significantly higher in the patients with more severe clinical 
symptoms than those with milder ones. More studies will be needed to verify 
the reliability of the current findings.  
Keywords: Procalcitonin, DPPIV, Severe symptoms, Mild symptoms, 
COVID-19 
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Introduction 
Coronavirus disease 2019 (COVID-19) caused by 
coronavirus has become the biggest global concern in 
2019-20. The Evidence indicates that the virus 
originated in wild animals and birds (1). Two 
coronavirus epidemics have occurred in the world with 
typical features of a respiratory syndrome called severe 
acute respiratory syndrome coronavirus (SARS-CoV) 
and Middle East respiratory syndrome coronavirus 
(MERS-CoV) (2, 3).  
The coronavirus-induced epidemic of acute 
respiratory syndrome (SARS-CoV-2) was first 
identified in December 2019 in Wuhan, China (4, 5). 
The COVID-19 patients may show severe or mild 
forms of the disease. People with serious infections 
often have other systemic diseases, such as diabetes, 
immunodeficiency, or cardiovascular diseases, which 
in turn accelerates the progression of the infection in 
them and sometimes leads to death (6-10).  
ARDS is the main cause of mortality in patients 
with Covid-19. ARDS is a common immunological 
event for SARS-COV, 2-SARS-COV, and MERS-
COV infections (6, 11). Like most other coronaviruses, 
viral outer membrane spike glycoproteins are the most 
important proteins that can react with host target 
proteins such as ACE2, CD26, Cyclophilins, and 
others, which are important for cell adhesion and 
virulence (12, 13).  
Dipeptidyl peptidase IV (DPPIV) also called 
CD26 is a 110 kDa cell surface glycoprotein with 
dipeptidase activity in the extracellular domain (14). 
DPPIV is a multifunctional cell surface protein in most 
cell types, including T lymphocytes, bronchial mucosa, 
and brush border of proximal tubules therefore, 
according to studies, it may play a role in the systemic 
spread of viral infections in humans (15-17).  
Procalcitonin is a diagnostic indicator of 
systemic infections and sepsis. There is a link between 
increased levels of Procalcitonin and leukocyte-
derived cytokines during infection and sepsis (18).  
Therefore, DPPIV and Procalcitonin markers 
may be useful as diagnostic markers to differentiate the 
patients with mild form COVID-19 from severe. 
Therefore, in the present study, the expression 
evaluation of DPPIV and Procalcitonin genes in 





This study was approved by the Research Ethics 
Committee, Shahid Beheshti University of Medical 
Sciences, Tehran, Iran 
(IR.SBMU.NRITLD.REC.1399.043), and all patients 
filled in informed consent. A total of 60 patients with 
mild (n=30) and severe forms (n=30) were included in 
this study.  Blood samples were taken from the patients 
with both severe COVID-19 who were admitted to the 
ICU as well as mild patients who were admitted to the 
infectious-internal medicine wards.  
 
 
Table 1: Sequence and the primers' characteristics. 





























328 65 152 
Annealing 60 56 56 
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RNA extraction and cDNA synthesis: RNA 
extraction was performed using the RNA Blood Mini 
Kit (Qiagen Cat no.52304, Germany) according to the 
manufacturer’s protocol. RNAs purity and 
concentration were determined using a Nanodrop 
spectrophotometer (Bio- Tek-USANanodrop). Viva 2-
steps RT-PCR Kit (Vivantis, Malaysia) was used to 
synthesize cDNA according to cDNA Kit's protocol. 
All cDNAs were stored at -20℃. The expression levels 
of DPPIV and Procalcitonin genes were determined 
using Cinna Green qPCR Mix, 2X (Cina Colon, Iran) 
by real-time PCR (Qiagen Rotor-Gene, Germany). 
18srRNA was used as the reference gene to normalize 
the RT-qPCR data. The sequences of the used primer 
are presented in Table 1. 
 
Quantitative Real-time PCR: before real-time PCR, 
the primers were prepared for DPPIV and 
Procalcitonin markers. The properties of which are 
shown in Table 1. To determine the efficiency of the 
primers, the real-time PCR reaction was performed 
with different primer dilutions (1 - 0.1 - 0.01 - 0.001), 
and the slope of the standard curve, which indicated the 
efficiency of the primers, was obtained. Moreover, the 
efficiencies of primers were confirmed by positive and 
negative control. The negative control experiment was 
performed without reverse transcriptase in each 
reaction buffer to confirm the specificity of the RT-
PCR assay. Target cDNAs obtained with reverse 
transcriptase were amplified by PCR for 40 cycles (one 
cycle: 95°C for 5 min) followed by 40 cycles 
consisting of denaturation, primers connection, 
amplification, and final amplification at 95°C for 15, 
56°C for 1 minute, 72℃ for 25 seconds, and 72℃ For 
5 min, respectively. 18srRNA gene was used as an 
internal control gene. Three synthesized cDNA 
samples from each patient were tested to express the 
reference and the studied genes. To determine the gene 
expression levels in the blood samples of both severe 
and mild patients the 2-ΔΔCt formula was used.  
 
Statistical analysis: The results were analyzed using 
SPSS Version 20. Data were expressed as the mean and 
standard deviations. The student t-test was used to 
analyze the difference or correlation between gene 
expression levels and Clinicopathologic Features. The 




The severe patients consisted of 21 (70%) males and 9 
(30%) females, and the group of patients with mild 
symptoms consisted of 20 (66.6%) males and 10 
(33.4%) females. There was no significant difference 
between the two groups in terms of average age.  
 
The Analysis of the studied biomarkers' expression: 
Dipeptidyl peptidase IV and Procalcitonin markers in 
the peripheral blood of patients with severe symptoms, 
were positive on 29/30 (96.60%) and 26/30 (86.60%), 
respectively. The positive rate of these markers in the 
group of patients with mild symptoms was 27/30 
(90%) and 25/30 (83.30%), respectively. There was a 
statistically significant difference between these two 
groups in terms of DDPIV and Procalcitonin (p<0.001) 
(Figure 1 & 2). 
The relative expression of both markers in 
patients with severe symptoms was compared to the 
patients with mild symptoms. In the patients with 
severe symptoms, the relative expression of Dipeptidyl 
peptidase IV and Procalcitonin was up-regulated to 
1.18 and 1.42 compared to patients with mild 
symptoms, respectively (Figure 3). 
 
Discussion 
This study has evaluated the relative expression of 
DPPIV and Procalcitonin in peripheral blood of 
patients with severe and mild-moderate symptoms of 
COVID-19. We have found that in the peripheral blood 
of patients with severe symptoms the expression levels 
of DPPIV and Procalcitonin are significantly up-
regulated compared to patients with mild-moderate 
symptoms. Procalcitonin is an amino acid polypeptide 
116, and its blood concentration is less than detectable 
in healthy individuals. However, it is increased in 
systemic inflammation, especially microbial infections 
(19). Increased Procalcitonin production mechanism  
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is not yet fully understood (20). DPPIV is an encoded 
protein by the DPP4 gene. This protein is an enzyme 
that is expressed at most levels of cells and is 
associated with immune regulation, signal 
transmission, and apoptosis (21) and as mentioned, it 
may play a role in the systemic spread of viral 
infections in humans. Levy et al, have examined the 
reduction of Procalcitonin in patients admitted to the 
intensive care unit (ICU) and compared the clinical 
outcome of patients with that. They reported that an 
increase in the survival of these patients was closely 
related to a decrease in serum Procalcitonin between 
two or three days of hospitalization (22). In the 
performed studies the increase of Procalcitonin 
expression in patients admitted to the ICU may indicate 
a lack of response to treatment in this group of patients. 
Yukioka et al., in their study on Prolactinonin, have 
reported that procalcitonin serum levels are a sensitive 
criterion for a clear distinction between microbial 
 
Figure 1. The percentage of positive Procalcitonin marker in patients with severe and mild symptoms. 
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infections and predictive reaction to treatment (23). In 
our study, there was an increase in the level of 
Procalcitonin expression in a group of patients with 
more severe symptoms than that of the group with mild 
symptoms, and this may be due to the appropriate 
reaction of a group of patients to the treatment 
protocol, who were hospitalized in the infectious-
internal medicine wards and improves the disease and 
shows milder symptoms, and the level of Procalcitonin 
decreases in this group. 
DPPIV is a multifunctional cellular surface 
protein in most cells. It has been shown that the S 
protein (spike) of the MERS-CoV virus using DPPIV 
as a cell surface receptor can cause infection (24, 25). 
The receptor remains intact among different species 
such as bats and humans, which in turn could cause 
extensive host suffering for viruses such as MERS-
CoV (26). Therefore, depending on the expression 
level of this protein at the level of cells such as T 
lymphocytes, bronchial mucosa, brush border of 
proximal tubules and such Coronavirus can infect more 
or fewer cells and cause disease, and this can be a 
treatment for MERS-CoV infection, in such a way that 
not only by blocking this receptor the virus can be 
prevented from the cells of the respiratory system, but 
also it can be removed from bloodstream (27, 28).  
Vankadari et al. have demonstrated the structure 
of the glycoprotein S (spike) model for the COVID-19, 
which is involved in adhesion to the host cell. They 
have also shown glycosylation of spike glycoprotein 
sites in the COVID-19, which distinguishes it from 
SARS, and COVID-19 coating structure in hiding from 
the immune system. There is also a key finding in this 
study: the second S1 of COVID-19 protein S 
potentially interacts with human CD26 (DPPIV) and 
the virus enters the cells through this(29-30). 
Therefore, according to this study, if DPPIV protein is 
increased, more viruses will enter the cells and the 
disease will be more severe. Our study also showed an 
increase in DPPIV expression in patients with more 
severe symptoms than in patients with milder 
symptoms. The marker can also be used as an effective 
treatment, and antibodies can be designed to block the 
CD26 marker and prevent COVID-19 from entering 
cells to prevent disease. 
 
Conclusion 
In the present study, using Ct values obtained from 
Real-time PCR reactions and calculations, it was 
shown that Procalcitonin and DPPIV proteins are 
markers that increase in patients with COVID-19 
infection. This increase is significantly higher in 
patients with more severe clinical symptoms than those 
 
Figure 3. The difference between marker expressions in patients with severe symptoms compared to patients with mild 
symptoms. 
DPPIV Procalcitonin
sever patient 1.18 1.42
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with milder symptoms. Obviously, due to the novelty 
of this disease, other studies are needed to complete the 
information to obtain ideal results for the diagnosis and 
treatment of this disease. 
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